<DOC>
	<DOCNO>NCT00467545</DOCNO>
	<brief_summary>This study evaluate safety telbivudine 21 month open-label treatment patient chronic hepatitis B complete CLDT600A2407 trial . Patients treated telbivudine core phase continue telbivudine patient treat entecavir core phase switch telbivudine patient willing enroll study .</brief_summary>
	<brief_title>An Extension Viral Kinetics Study Telbivudine Entecavir Adults With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>The patient complete previous CLDT600A2407 study able immediately enter extension study study drug discontinuation Patient willing able comply study drug regimen study requirement The patient willing able provide write informed consent participate extension study . Patient pregnant breastfeeding . Patient coinfected HCV , HDV , HIV . History malignancy organ system , treat untreated , within past 5 year exception localize basal cell carcinoma skin . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HBeAg-positive</keyword>
	<keyword>chronic hepatitis B</keyword>
	<keyword>telbivudine</keyword>
</DOC>